Cancer centers are re-evaluating their relationships with health care companies, including when, if ever, doctors and researchers should serve on corporate boards. Here are some hospital executives and cancer researchers who sit on the boards of publicly traded companies, in dual roles that may raise questions about conflicts of interest.

Dr. Laurie H. Glimcher

Image Credit...

President and chief executive of the Dana-Farber Cancer Institute, Boston

Company: Dr. Glimcher sits on the boards of the British drugmaker GlaxoSmithKline and Waters Corp., a laboratory equipment and software company.

Outside Compensation: Dr. Glimcher joined the board of GlaxoSmithKline in September of 2017; she received $101,000 in total compensation from the company that year, plus compensation of $285,440 from Waters that year.